Literature DB >> 12062602

Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning.

Numa Cellini1, Alessio G Morganti, Gian C Mattiucci, Vincenzo Valentini, Mariavittoria Leone, Stefano Luzi, Riccardo Manfredi, Nicola Dinapoli, Cinzia Digesu', Daniela Smaniotto.   

Abstract

PURPOSE: Conformal therapy of prostate cancer is based on high-dose irradiation to the entire prostate gland. The aim of this study was to analyze the pattern of intraprostatic recurrence in patients undergoing external beam radiotherapy (EBRT) at a dose of 65-70 Gy to evaluate whether conventional radiotherapy doses are adequate to control microscopic disease outside the primary tumor and therefore whether high-dose irradiation can be exclusively focused on the macroscopic disease. METHODS AND MATERIALS: The clinical and radiologic reports of 118 patients with prostate cancer undergoing EBRT (64.8-70.2 Gy) combined with hormonal therapy were evaluated. In all patients, before and after therapy, the size and site of the primary neoplasm within the prostate were assessed by clinical examination and imaging studies.
RESULTS: With a median follow-up of 45 months (range 14-119), the 5-year actuarial local control rate was 83.9%. Twelve patients had an intraprostatic recurrence, with the appearance of a new nodule (in 5 patients with a complete response after therapy) or increased nodular size compared with the minimal size (in the 7 other patients). In all patients, on the basis of a semiquantitative evaluation of the site of recurrence, this was shown to originate within the initial tumor volume.
CONCLUSION: The results of this analysis seem to confirm some histologic findings observed in patients undergoing prostatectomy for local recurrence after radiotherapy that suggest that local recurrence usually originates in the primary tumor rather than in focal prostatic intraepithelial neoplasia. This observation might justify the application of conformal therapy procedures aimed at identifying the gross tumor volume, in the phase of boost, exclusively with the primary tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12062602     DOI: 10.1016/s0360-3016(02)02795-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  52 in total

Review 1.  Functional MRI for radiotherapy dose painting.

Authors:  Uulke A van der Heide; Antonetta C Houweling; Greetje Groenendaal; Regina G H Beets-Tan; Philippe Lambin
Journal:  Magn Reson Imaging       Date:  2012-07-06       Impact factor: 2.546

Review 2.  Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Authors:  Stefano Arcangeli; Linda Agolli; Vittorio Donato
Journal:  Rep Pract Oncol Radiother       Date:  2014-09-10

3.  Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.

Authors:  Yu Kuang; Lili Wu; Emily Hirata; Kyle Miyazaki; Miles Sato; Sandi A Kwee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

4.  The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy.

Authors:  Antonio José Conde-Moreno; Carlos Ferrer-Albiach; Mercedes Zabaleta-Meri; Xavi J Juan-Senabre; Agustín Santos-Serra
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 5.  MR imaging of treated prostate cancer.

Authors:  Hebert Alberto Vargas; Cecilia Wassberg; Oguz Akin; Hedvig Hricak
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

6.  Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy.

Authors:  C Onal; S Sonmez; G Erbay; O C Guler; G Arslan
Journal:  Br J Radiol       Date:  2013-12-06       Impact factor: 3.039

7.  Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost.

Authors:  Michael Pinkawa; Richard Holy; Marc D Piroth; Jens Klotz; Sandra Nussen; Thomas Krohn; Felix M Mottaghy; Martin Weibrecht; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

8.  Dosimetric benefit of DMLC tracking for conventional and sub-volume boosted prostate intensity-modulated arc radiotherapy.

Authors:  Tobias Pommer; Marianne Falk; Per R Poulsen; Paul J Keall; Ricky T O'Brien; Peter Meidahl Petersen; Per Munck af Rosenschöld
Journal:  Phys Med Biol       Date:  2013-03-14       Impact factor: 3.609

9.  Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy.

Authors:  Gilles Crehange; Devan Krishnamurthy; J Adam Cunha; Barby Pickett; John Kurhanewicz; I-Chow Hsu; Alexander R Gottschalk; Katsuto Shinohara; Mack Roach; Jean Pouliot
Journal:  Radiother Oncol       Date:  2013-11-11       Impact factor: 6.280

10.  Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study.

Authors:  Elnasif Arrayeh; Antonio C Westphalen; John Kurhanewicz; Mack Roach; Adam J Jung; Peter R Carroll; Fergus V Coakley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.